Zentalis Pharmaceuticals shares are trading lower after the FDA placed a partial clinical hold on ZN-c3-001, DENALI, and TETON monotherapy studies of Azenosertib following two recent deaths due to presumed sepsis in the DENALI study.
Portfolio Pulse from Benzinga Newsdesk
Zentalis Pharmaceuticals shares are trading lower after the FDA placed a partial clinical hold on ZN-c3-001, DENALI, and TETON monotherapy studies of Azenosertib following two recent deaths due to presumed sepsis in the DENALI study.
June 18, 2024 | 11:29 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Zentalis Pharmaceuticals shares are trading lower after the FDA placed a partial clinical hold on ZN-c3-001, DENALI, and TETON monotherapy studies of Azenosertib following two recent deaths due to presumed sepsis in the DENALI study.
The FDA's partial clinical hold on Zentalis Pharmaceuticals' Azenosertib studies due to safety concerns, including two recent deaths, is likely to negatively impact the company's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100